These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 31200360)

  • 61. NICE and the challenge of cancer drugs.
    Raftery J
    BMJ; 2009 Jan; 338():b67. PubMed ID: 19141502
    [No Abstract]   [Full Text] [Related]  

  • 62. Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs.
    Mancini R; McBride A; Kruczynski M
    Oncology (Williston Park); 2013 Sep; 27(9):865-6, 871. PubMed ID: 24282981
    [No Abstract]   [Full Text] [Related]  

  • 63. Multimodality cancer care and implications for episode-based payments in cancer.
    Gondi S; Wright AA; Landrum MB; Zubizarreta J; Chernew ME; Keating NL
    Am J Manag Care; 2019 Nov; 25(11):537-538. PubMed ID: 31747230
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014.
    Winn AN; Keating NL; Trogdon JG; Basch EM; Dusetzina SB
    JAMA Oncol; 2018 Apr; 4(4):580-581. PubMed ID: 29470578
    [TBL] [Abstract][Full Text] [Related]  

  • 65. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The new Medicare bill: far-reaching effects on cancer treatment.
    Bailes JS; Coleman T
    Clin Adv Hematol Oncol; 2004 May; 2(5):292-4. PubMed ID: 16163195
    [TBL] [Abstract][Full Text] [Related]  

  • 67. FDA approvals of old drugs put new pressure on payers.
    Silverman E
    Manag Care; 2011 May; 20(5):30-1. PubMed ID: 21667624
    [No Abstract]   [Full Text] [Related]  

  • 68. Should oncologists support the Affordable Care Act?
    Kantarjian H; Steensma D; Light D
    Lancet Oncol; 2013 Dec; 14(13):1258-9. PubMed ID: 24275127
    [No Abstract]   [Full Text] [Related]  

  • 69. Cancer research in the United States: dying by a thousand paper cuts.
    Kantarjian H; Stewart DJ; Zwelling L
    Cancer; 2013 Nov; 119(21):3742-5. PubMed ID: 23744791
    [No Abstract]   [Full Text] [Related]  

  • 70. Bending the cost curve in cancer care.
    Good M; Good CB
    N Engl J Med; 2011 Aug; 365(7):674-5; author reply 675-6. PubMed ID: 21848478
    [No Abstract]   [Full Text] [Related]  

  • 71. Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries.
    Zhang Y; Hueser HC; Hernandez I
    J Manag Care Spec Pharm; 2017 Feb; 23(2):247-254. PubMed ID: 28125371
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Trends in the 2012 Eisai Oncology Digest: insurance and cost obstacles in cancer treatment.
    Am J Manag Care; 2012 Dec; 18(5 Spec No.):SP222-3. PubMed ID: 23301711
    [No Abstract]   [Full Text] [Related]  

  • 73. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
    Beatty PA; Laking GR
    J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
    [No Abstract]   [Full Text] [Related]  

  • 74. Attitude of Iranian Medical Oncologists Toward Economic Aspects, and Policy-making in Relation to New Cancer Drugs.
    Daroudi R; Mirzania M; Zendehdel K
    Int J Health Policy Manag; 2015 Oct; 5(2):99-105. PubMed ID: 26927395
    [TBL] [Abstract][Full Text] [Related]  

  • 75. NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.
    Becker PS; Griffiths EA; Alwan LM; Bachiashvili K; Brown A; Cool R; Curtin P; Dinner S; Gojo I; Hicks A; Kallam A; Kidwai WZ; Kloth DD; Kraut EH; Landsburg D; Lyman GH; Miller R; Mukherjee S; Patel S; Perez LE; Poust A; Rampal R; Rosovsky R; Roy V; Rugo HS; Shayani S; Vasu S; Wadleigh M; Westbrook K; Westervelt P; Burns J; Keller J; Pluchino LA
    J Natl Compr Canc Netw; 2020 Jan; 18(1):12-22. PubMed ID: 31910384
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
    Sobrero A; Bruzzi P
    J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
    [No Abstract]   [Full Text] [Related]  

  • 77. [Dose reassessment: An answer to the high cost of drugs used in oncology?].
    Levêque D
    Bull Cancer; 2019 Sep; 106(9):719-724. PubMed ID: 31202558
    [No Abstract]   [Full Text] [Related]  

  • 78. Gaining Coverage Through Medicaid Or Private Insurance Increased Prescription Use And Lowered Out-Of-Pocket Spending.
    Mulcahy AW; Eibner C; Finegold K
    Health Aff (Millwood); 2016 Sep; 35(9):1725-33. PubMed ID: 27534776
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Clinical practice guidelines for the adverse events in medical oncology].
    Isobe T; Hayashi M; Tsubata Y
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():45-50. PubMed ID: 25831722
    [No Abstract]   [Full Text] [Related]  

  • 80. Cancer research in the United States: A critical review of current status and proposal for alternative models.
    Kantarjian HM; Prat F; Steensma DP; Kurzrock R; Stewart DJ; Sekeres MA; Leveque J
    Cancer; 2018 Jul; 124(14):2881-2889. PubMed ID: 29757456
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.